Patents by Inventor Brian M. Fendly

Brian M. Fendly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ErbB2 ANTIBODIES
    Publication number: 20180282428
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Brian M. Fendly, Gail Dianne Phillips, Richard Scheuermann, Jonathan W. Uhr
  • ANTI-ErbB2 ANTIBODIES
    Publication number: 20170190786
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: August 11, 2016
    Publication date: July 6, 2017
    Inventors: Brian M. Fendly, Gail Dianne Phillips, Richard H. Scheuermann, Jonathan W. Uhr
  • ANTI-ErbB2 ANTIBODIES
    Publication number: 20150252113
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death-via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: October 10, 2014
    Publication date: September 10, 2015
    Inventors: Brian M. FENDLY, Gail Dianne PHILLIPS, Richard H. SCHEUERMANN, Jonathan W. UHR
  • ANTI-ERBB2 ANTIBODIES
    Publication number: 20130195845
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: March 27, 2012
    Publication date: August 1, 2013
    Inventors: Brian M. Fendly, Gail Dianne Phillips
  • ANTI-ErbB2 ANTIBODIES
    Publication number: 20110033460
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: October 22, 2010
    Publication date: February 10, 2011
    Inventors: Brian M. Fendly, Gail Dianne Phillips, Richard H. Scheuermann, Jonathan W. Uhr
  • Anti-ErbB2 antibodies
    Patent number: 7371376
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventor: Brian M. Fendly
  • HIV env antibodies
    Patent number: 7041293
    Abstract: The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
  • Agonist antibodies
    Patent number: 6737249
    Abstract: Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: May 18, 2004
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Paul J. Carter, Brian M. Fendly, Austin L. Gurney
  • Method of treating tumor cells by inhibiting growth factor receptor function
    Publication number: 20020192211
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Application
    Filed: June 20, 2002
    Publication date: December 19, 2002
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 6399063
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: June 4, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 6387371
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: May 14, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Agonist antibodies
    Patent number: 6342220
    Abstract: Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: August 25, 1997
    Date of Patent: January 29, 2002
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Paul J. Carter, Brian M. Fendly, Austin L. Gurney
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 6165464
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: December 26, 2000
    Assignee: Genetech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Method for making unclipped HIV envelope protein
    Patent number: 5849533
    Abstract: Methods for making unclipped HIV env proteins are provided. According to the methods, a genetically engineered cell line comprising an nucleic acid sequence encoding an HIV env protein is cultured to produce unclipped HIV env protein, which is recovered from the cell culture.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: December 15, 1998
    Assignee: Genetech, Inc.
    Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Elorian M. Wurm
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5772997
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treatment tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: June 30, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the her2 receptor
    Patent number: 5770195
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: June 23, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5725856
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: March 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5720954
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • In vivo tumor detection assay
    Patent number: 5720937
    Abstract: In vivo assay methods for detecting tumors having amplified expression of the HER2 receptor are disclosed. In the assay, cells within the body of a mammal are exposed to an antibody which specifically binds to the extracellular domain of the HER2 receptor and inhibits growth in vitro of SK-BR-3 breast tumor cells which overexpress p185.sup.HER2. The antibody is generally tagged with a radioactive isotope to permit the extent of binding of the antibody to the cells to be quantified.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: February 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5677171
    Abstract: Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: October 14, 1997
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly